Clinical Trials Browser

INDUSTRY × Has announcements × Trastuzumab × Clear all

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 3 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT03615326 2025-12-11

MK-3475-811

Phase 3 Completed

738 enrolled 22 charts 7 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 2 FDA

Breast Neoplasms

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Phase 3 Completed

1,486 enrolled 37 charts 2 FDA

Breast Neoplasms

NCT02492711 2025-03-17

SOPHIA

Phase 3 Completed

624 enrolled 17 charts 3 FDA

Neoplasm Metastasis

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Phase 2 Completed

117 enrolled 21 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT03493854 2024-06-26

FeDeriCa

Phase 3 Completed

500 enrolled 28 charts 3 FDA

Breast Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

Phase 2 Completed

612 enrolled 30 charts 3 FDA

Brain Neoplasms, Breast Neoplasms

NCT01566721 2021-04-27

SafeHER

Phase 3 Completed

2,577 enrolled 16 charts 2 FDA

Breast Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Phase 3 Completed

596 enrolled 31 charts 2 FDA

Breast Neoplasms